Core Points - Jiangzhong Pharmaceutical Co., Ltd. held its 8th meeting of the 10th Board of Directors on September 25, 2025, where several key resolutions were passed [1] Group 1: Acquisition and Investment - The company approved the acquisition of 70% equity in Jingcheng Huyao for a maximum price of 70.78393 million yuan, aiming to enhance its OTC product matrix in traditional Chinese medicine [2] - The company plans to reduce its investment in Sanghai Pharmaceutical by decreasing its registered capital by 39 million yuan, maintaining its shareholding ratio [4] - The company will adjust the disposal plan for its subsidiary, Jisheng Pharmaceutical, by merging it with the Sangji Project Company instead of transferring its equity [6] Group 2: Project Development - Jiangzhong Pharmaceutical's subsidiary, Jiangzhong Decoction Pieces Co., Ltd., will initiate the second phase of the Smart Decoction Center project with an estimated investment of 11.15 million yuan [3] Group 3: Dividend Distribution - The company announced a cash dividend of 0.5 yuan per share for the first half of 2025, totaling 317.498 million yuan based on a total share capital of 634,996,022 shares [9] - The dividend distribution plan was approved at the company's first extraordinary general meeting on September 8, 2025 [8]

Core Viewpoint - Jiangzhong Pharmaceutical announced a cash dividend of 0.5 yuan per share (tax included) for the first half of 2025, with the record date set for October 10, 2025, and the ex-dividend date on October 13, 2025 [2] Summary by Category - **Dividend Announcement** - The company will distribute a cash dividend of 0.5 yuan per share for the first half of 2025 [2] - The dividend is inclusive of tax [2] - **Key Dates** - The record date for the dividend is October 10, 2025 [2] - The ex-dividend date is October 13, 2025 [2]

A 股每股现金红利 0.5 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/10/10 | － | 2025/10/13 | 2025/10/13 | 差异化分红送转： 否 一、通过分配方案的股东会届次和日期 证券代码：600750 证券简称：江中药业 公告编号：2025-050 江中药业股份有限公司 2025 年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 本次利润分配方案经江中药业股份有限公司（以下简称"公司"）2025 年 9 月 8 日的 2025 年第一次临时股东会审议通过。 二、分配方案 1.发放年度：2025 年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的 ...

Core Viewpoint - Jiangzhong Pharmaceutical (600750) announced the acquisition of 70% equity in Anhui Jingcheng Huyao Pharmaceutical Co., Ltd. for a price not exceeding 70.78393 million yuan, aiming to enhance its OTC product matrix with traditional Chinese medicine products [1] Group 1: Acquisition Details - The acquisition will allow Jiangzhong Pharmaceutical to supplement its product offerings in the traditional Chinese medicine sector, particularly in the health supplement category [1] - Anhui Jingcheng Huyao, established in November 2013 with a registered capital of 51 million yuan, focuses on the R&D, production, and sales of traditional Chinese medicine [1] - The core products of Jingcheng Huyao include Liuwei Dihuang Oral Liquid, Nao Li Jing Syrup, and Nao Li Jing Capsules [1] Group 2: Company Background - Jingcheng Huyao was previously known as Bengbu Traditional Chinese Medicine Factory, founded in 1968, and was fully acquired by Peitian Group in 2015 [1] - The company was listed on the Specialized and New Board of Anhui Stock Custody Center in October 2021 [1] Group 3: Operational Challenges - Peitian Group, the current owner of Jingcheng Huyao, has faced operational difficulties due to poor management, market changes, and heavy debt burdens, leading to a debt crisis in 2018 [3] - The company underwent a restructuring process initiated by the government and asset management companies to address its financial issues [3] - As part of the restructuring plan, the court approved a merger and restructuring plan for Peitian Group and its subsidiaries, including Jingcheng Huyao, in September 2024 [3]

每经AI快讯，江中药业（SH 600750，收盘价：21.8元）9月26日晚间发布公告称，公司第十届第八次董 事会会议于2025年9月25日在公司会议室以现场结合视频方式召开。会议审议了《关于对外转让桑海制 药51.0044%股权的议案》等文件。 2025年1至6月份，江中药业的营业收入构成为：医药工业占比99.64%，酒业占比0.25%，其他业务占比 0.11%。 （记者 曾健辉） 截至发稿，江中药业市值为138亿元。 每经头条（nbdtoutiao）——5年增长33倍，这类新险种卖爆了，身边很多人都需要，30多家险企蜂拥而 入⋯⋯ ...

证券代码：600750 证券简称：江中药业 公告编号：2025-049 江中药业股份有限公司 一、关于拟收购精诚徽药 70%股权的议案 表决情况：9 票同意，0 票反对，0 票弃权，通过本议案。 为补充中药补益类品种、丰富 OTC 产品矩阵，同意公司作为意向受让方以 自有资金通过公开摘牌方式收购安徽省精诚徽药药业有限公司（以下简称"精 诚徽药"）70%股权。精诚徽药主要从事中成药的研发、生产和销售，聚焦中药 补益类 OTC 产品，核心品种为六味地黄口服液、脑力静糖浆及脑力静胶囊。本 次拟收购标的股权对应的成交价格不高于 7,078.393 万元，并授权经理层具体 办理此次交易相关事宜。 本次公开摘牌结果尚存在不确定性。若成功摘牌，公司将持有精诚徽药 70%股权，实现对精诚徽药的实际控制权，并将其纳入公司合并报表范围。交易 完成后，公司及精诚徽药可能面临市场环境变化、管理整合以及行业与政策调 整等方面的风险。公司将密切关注相关动态，审慎评估并积极采取有效措施进 行风险防范与化解。 二、关于控股子公司江中饮片开展智慧代煎中心（二期）项目的议案 第十届董事会第八次会议决议公告 表决情况：9 票同意，0 票反对，0 ...

2025-050 证券代码：600750 证券简称：江中药业 公告编号： 江中药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 差异化分红送转： 否 一、通过分配方案的股东会届次和日期 本次利润分配方案经江中药业股份有限公司（以下简称"公司"）2025 年 9 月 8 日的2025年第一次临时股东会审议通过。 二、分配方案 1.发放年度：2025年半年度 每股分配比例 A 股每股现金红利0.5元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/10/10 | － | 2025/10/13 | 2025/10/13 | 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本 ...

Core Insights - On September 22, brokerages set target prices for listed companies, with notable increases for Gao Weida, SAIC Motor, and Haitian Flavoring, showing target price increases of 98.76%, 37.72%, and 27.18% respectively, across the software development, passenger vehicle, and seasoning industries [1][3] Group 1: Target Price Increases - Gao Weida received a target price of 51.50 yuan, reflecting a target price increase of 98.76% [3] - SAIC Motor's target price was set at 26.25 yuan, indicating a 37.72% increase [3] - Haitian Flavoring's target price reached 50.25 yuan, with a 27.18% increase [3] Group 2: Rating Adjustments - One company, Tebian Electric Apparatus, had its rating upgraded from "Hold" to "Strong Buy" by China Merchants Securities [4] - One company, Jiangling Motors, had its rating downgraded from "Buy" to "Hold" by Industrial Securities [5] Group 3: First Coverage - On September 22, brokerages initiated coverage on nine companies, including Jiangling Motors with a rating of "Hold" from Industrial Securities, and Ximai Food with a "Hold" rating from Shanxi Securities [6] - Gao Weida received a "Buy" rating from Dongwu Securities [6] - Other companies receiving coverage include Hengxin Life with a "Hold" rating and Xianglou New Materials with a "Hold" rating [6]

9月22日，A股市场整体上涨。 截至收盘，上证指数收报3828.58点，上涨0.22%；深证成指收报13157.97点，上涨0.67%；创业板指收报3107.89 点，上涨0.55%。两市合计成交21214.83亿元，较上一交易日减少2023.47亿元。 1. 两市主力资金净流出近150亿元 | | | 沪深两市最近五个交易日主力资金流向情况(亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | 净流入金额 开盘净流入 | 尾盘净流入 | 超大单净买入 | | 2025-9-22 | -149.51 | -77.29 | 37. 32 | -12. 91 | | 2025-9-19 | -431.42 | -147.94 | -31. 05 | -206. 34 | | 2025-9-18 | -760.44 | -203. 53 | -196. 21 | -332. 00 | | 2025-9-17 | -328.39 | -128. 05 | -39.90 | -150. 90 | | 2025-9-16 | -165.54 | -44. 85 | 4. 6 ...

Macroeconomic Insights - Consumer spending shows improvement, with automotive retail and high-end liquor prices rebounding due to seasonal effects[5] - Infrastructure special bond issuance is accelerating, while real estate sales are recovering, although land market activity is cooling[5] - Industrial production is generally declining, with power generation and steel industries adjusting due to demand and profit impacts[5] Federal Reserve and Global Market Trends - The Federal Reserve has cut interest rates by 25 basis points, with expectations for two more cuts this year, indicating a cautious approach to monetary policy[6] - Major stock markets have generally risen, with the S&P 500 up 1.2% and emerging markets outperforming developed markets[6] - The 10-year U.S. Treasury yield increased by 8 basis points to 4.14%, reflecting market adjustments post-rate cut[6] Investment Strategy and Market Outlook - Market adjustments present opportunities, with a belief that the Chinese stock market will continue to rise, driven by a shift in asset demand and capital market reforms[8] - The consensus on economic expectations is cautiously optimistic, with signs of stabilization in corporate revenue and inventory growth[9] - Emerging technology sectors, particularly AI and semiconductor industries, are expected to lead market performance, with recommendations for strategic allocations in these areas[10] Sector Performance and Recommendations - The Hong Kong stock market is highlighted for its high dividend yield and attractive valuation compared to A-shares, with a cash dividend ratio of 44% versus 36% for A-shares[26] - The technology sector remains a focal point, with ongoing capital expenditure expansion and a favorable environment for innovation and growth[10] - Recommendations include increasing allocations in consumer sectors and traditional industries benefiting from economic recovery and policy support[10]